Get the Stockscreener App
26.91
3.60%
0.935
Cg Oncology Inc stock is traded at $26.91, with a volume of 542.48K.
It is up +3.60% in the last 24 hours and up +3.48% over the past month.
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
See More
Previous Close:
$25.98
Open:
$26.08
24h Volume:
542.48K
Relative Volume:
0.65
Market Cap:
$2.05B
Revenue:
-
Net Income/Loss:
$-64.16M
P/E Ratio:
-21.19
EPS:
-1.2702
Net Cash Flow:
$-69.06M
1W Performance:
+4.73%
1M Performance:
+3.48%
6M Performance:
-3.36%
1Y Performance:
-25.09%
1-Day Range:
$25.74
$27.20
1-Week Range:
$24.85
$27.20
52-Week Range:
$14.80
$40.47
Cg Oncology Inc Stock (CGON) Company Profile
Name
Cg Oncology Inc
Sector
Industry
Phone
(949) 419-6203
Address
400 SPECTRUM CENTER DRIVE, IRVINE
Compare CGON with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CGON
Cg Oncology Inc
|
26.91 | 1.99B | 0 | -64.16M | -69.06M | -1.2702 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Cg Oncology Inc Stock (CGON) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-10-25 | Resumed | Goldman | Buy |
| May-02-25 | Initiated | JP Morgan | Overweight |
| Apr-16-25 | Initiated | Scotiabank | Sector Perform |
| Jan-07-25 | Initiated | TD Cowen | Buy |
| Oct-24-24 | Initiated | UBS | Buy |
| Sep-23-24 | Initiated | RBC Capital Mkts | Outperform |
| Aug-28-24 | Initiated | ROTH MKM | Buy |
| Jun-28-24 | Initiated | BofA Securities | Buy |
| Feb-20-24 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-20-24 | Initiated | Goldman | Neutral |
| Feb-20-24 | Initiated | Morgan Stanley | Overweight |
| Feb-14-24 | Initiated | H.C. Wainwright | Buy |
View All
Cg Oncology Inc Stock (CGON) Latest News
CG Oncology’s Bladder Cancer Drug Shows Strong Clinical Data, Drives Optimism Despite Price Target Cut - MSN
H.C. Wainwright Reiterates a Buy on CG Oncology (CGON), Keeps the PT - Yahoo Finance
Piper Sandler initiates coverage of oncology companies - MSN
CG Oncology initiated with an Overweight at Piper Sandler - TipRanks
Technical Models Detect Momentum Build in CG Oncology Inc.Portfolio Return Report & Real-Time Price Movement Reports - classian.co.kr
Why CG Oncology Inc. stock attracts strong analyst attentionWeekly Stock Report & Growth Oriented Trading Recommendations - 선데이타임즈
Will CG Oncology Inc. stock go up soonJuly 2025 Macro Moves & Accurate Intraday Trade Tips - Newser
How CG Oncology Inc. stock performs during market volatilityGold Moves & High Accuracy Investment Signals - Newser
What MACD signals say about CG Oncology Inc.July 2025 Retail & Technical Pattern Alert System - Newser
CG Oncology price target lowered to $62 from $63 at BofA - MSN
Price Reversal in CG Oncology Inc. Traders Watch Closely2025 Valuation Update & Free Risk Controlled Daily Trade Plans - newsimpact.co.kr
Statistical indicators supporting CG Oncology Inc.’s strengthWeekly Trading Summary & Free Weekly Watchlist of Top Performers - Newser
Intraday pattern recognizer results for CG Oncology Inc.Trade Exit Summary & Verified Stock Trade Ideas - Newser
What moving averages say about CG Oncology Inc.2025 Support & Resistance & High Yield Stock Recommendations - Newser
Comparing CG Oncology Inc. in custom built stock radarsQuarterly Trade Report & Weekly Momentum Picks - Newser
How does CG Oncology Inc. score in quality rankings2025 Buyback Activity & AI Enhanced Trading Signals - thegnnews.com
What makes CG Oncology Inc. stock price move sharply2025 Year in Review & High Accuracy Investment Entry Signals - thegnnews.com
Using R and stats models for CG Oncology Inc. forecastingJuly 2025 Trade Ideas & Safe Swing Trade Setup Alerts - Newser
Does CG Oncology Inc. qualify in momentum factor screeningJuly 2025 Catalysts & Community Trade Idea Sharing Platform - Newser
What earnings revisions data tells us about CG Oncology Inc.Product Launch & Stepwise Trade Signal Implementation - Newser
Real time breakdown of CG Oncology Inc. stock performanceJuly 2025 Trends & Weekly Return Optimization Alerts - Newser
CG Oncology Inc. stock trend outlook and recovery pathTrade Risk Assessment & Growth Oriented Trading Recommendations - Newser
Q3 Earnings Forecast for CG Oncology Issued By HC Wainwright - Defense World
Cantor Fitzgerald Lowers Earnings Estimates for CG Oncology - Defense World
New Product Launches: Will They Boost CG Oncology Inc. Stock in 2025Stop Loss & Free AI Powered Buy and Sell Recommendations - Newser
ETF Analysts See 14% Upside for Humankind US Stock ETF - AInvest
CG Oncology, Inc. (NASDAQ:CGON) Given Average Recommendation of “Buy” by Brokerages - Defense World
CG Oncology’s Q2 2025: Clinical Advances and Legal Wins - The Globe and Mail
Analysts Conflicted on These NA Names: Tempus AI, Inc. Class A (TEM) and CG Oncology, Inc. (CGON) - The Globe and Mail
CG Oncology Inc. Attempts Reversal From Key SupportExpert Verified Stock Trade Ideas Backed by Data - beatles.ru
CG Oncology 2025 Q1 Earnings Net Loss Widens Sharply - AInvest
Zurcher Kantonalbank Zurich Cantonalbank Acquires 7,600 Shares of CG Oncology, Inc. (NASDAQ:CGON) - Defense World
Buy Rating for CG Oncology, Inc. Driven by Promising Clinical Data and Strategic Advancements - NewsBreak: Local News & Alerts
CG Oncology shares rise 1.64% intraday after reporting positive earnings and clinical trial results. - AInvest
CG Oncology Reports Q2 GAAP EPS of -$0.54, Cash Holdings at $661.1 Million - AInvest
CG Oncology's Q2 2025: Balancing Burn Rate and Breakthroughs in the Race for Bladder Cancer Innovation - AInvest
CG Oncology, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 - MarketScreener
Cg Oncology (CGON) Q2 Loss Widens 93% - The Motley Fool
Cg Oncology (CGON) Q2 Loss Widens 93% - Nasdaq
Earnings Flash (CGON) CG Oncology Posts Q2 Net Loss $0.54 a Share, vs. FactSet Est of $0.46 Loss - MarketScreener
CG Oncology reports Q2 EPS (54c), consensus (44c) - TipRanks
CG Oncology Reports Q2 Financials, Announces BOND-003 Durability Data. - AInvest
CG Oncology Reports Second Quarter 2025 Financial Results and Provides Business Updates - The Globe and Mail
How King & Spalding Beat $2B Claim In Biopharma Fight - Law360
CG Oncology (CGON) Projected to Release Earnings on Thursday - Defense World
Is CG Oncology Inc. a good long term investmentSuperior return velocity - Jammu Links News
Does CG Oncology Inc. stock perform well during market downturnsGet ahead with breakthrough trading ideas - Jammu Links News
What analysts say about CG Oncology Inc. stockInvest confidently with real-time market updates - Jammu Links News
How does CG Oncology Inc. generate profit in a changing economyBreakthrough profit margins - Jammu Links News
CG Oncology, Inc. (CGON) Reports 75.5% Complete Response in Bladder Cancer Trial - MSN
When is CG Oncology Inc. stock expected to show significant growthInvest confidently with real-time data analysis - Jammu Links News
Cg Oncology Inc Stock (CGON) Financials Data
Revenue
Net Income
Cash Flow
EPS
Cg Oncology Inc Stock (CGON) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| POST LEONARD E | Director |
Jul 17 '25 |
Sale |
28.00 |
2,000 |
56,000 |
0 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):